Researchers studied the effect of dapagliflozin on cumulative sodium excretion in patients with type 2 diabetes and preserved kidney function while sodium intake was being strictly controlled.
Scientific statement by AHA detailing the current understanding of menopause transition and its impact on the risk for postmenopausal cardiovascular disease.
In this phase 2 trial, patients with hypercholesterolemia and clinical atherosclerotic cardiovascular disease were recruited from 85 sites across 20 countries.